Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shore

Showing results (501-510 of 591) with videos related to

Pageof 60
Sort By:
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Urologic Oncology|April 20, 2020
Development and evaluation of the MiCheck test for aggressive prostate cancerNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
American Journal of Medical Genetics|July 23, 1998
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigreesC A Kaufmann, B Suarez, D Malaspina, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
American Journal of Medical Genetics|July 23, 1998
Genome-wide search for schizophrenia susceptibility loci: the NIMH Genetics Initiative and Millennium ConsortiumC R Cloninger, C A Kaufmann, S V Faraone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
The Journal of Urology|June 2, 2021
Reply by AuthorsKevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 60

Showing results (501-510 of 591) with videos related to

Sort By:
Pageof 60
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Urologic Oncology|April 20, 2020
Development and evaluation of the MiCheck test for aggressive prostate cancerNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
American Journal of Medical Genetics|July 23, 1998
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigreesC A Kaufmann, B Suarez, D Malaspina, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
American Journal of Medical Genetics|July 23, 1998
Genome-wide search for schizophrenia susceptibility loci: the NIMH Genetics Initiative and Millennium ConsortiumC R Cloninger, C A Kaufmann, S V Faraone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancerK Fizazi, K N Chi, N D Shore, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
The Journal of Urology|June 2, 2021
Reply by AuthorsKevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 60